EP0663839A4 - Ibuprofen-h 2? antagonist combinations. - Google Patents

Ibuprofen-h 2? antagonist combinations.

Info

Publication number
EP0663839A4
EP0663839A4 EP93921709A EP93921709A EP0663839A4 EP 0663839 A4 EP0663839 A4 EP 0663839A4 EP 93921709 A EP93921709 A EP 93921709A EP 93921709 A EP93921709 A EP 93921709A EP 0663839 A4 EP0663839 A4 EP 0663839A4
Authority
EP
European Patent Office
Prior art keywords
ibuprofen
antagonist combinations
antagonist
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93921709A
Other languages
German (de)
French (fr)
Other versions
EP0663839A1 (en
Inventor
Robert T Sims
William Slivka
Thomas N Gates
Robert Mcmahon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Johnson and Johnson Consumer Inc
Original Assignee
Merck and Co Inc
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc, McNeil PPC Inc filed Critical Merck and Co Inc
Publication of EP0663839A1 publication Critical patent/EP0663839A1/en
Publication of EP0663839A4 publication Critical patent/EP0663839A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
EP93921709A 1992-09-29 1993-09-21 Ibuprofen-h 2? antagonist combinations. Withdrawn EP0663839A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95344092A 1992-09-29 1992-09-29
US953440 1992-09-29
PCT/US1993/008947 WO1994007541A1 (en) 1992-09-29 1993-09-21 Ibuprofen-h2 antagonist combinations

Publications (2)

Publication Number Publication Date
EP0663839A1 EP0663839A1 (en) 1995-07-26
EP0663839A4 true EP0663839A4 (en) 1998-06-03

Family

ID=25493996

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921709A Withdrawn EP0663839A4 (en) 1992-09-29 1993-09-21 Ibuprofen-h 2? antagonist combinations.

Country Status (6)

Country Link
EP (1) EP0663839A4 (en)
JP (1) JPH08502254A (en)
AU (1) AU4931693A (en)
CA (1) CA2144155A1 (en)
MX (1) MX9306006A (en)
WO (1) WO1994007541A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028988A1 (en) 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
SE0000774D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE60237087D1 (en) 2001-06-01 2010-09-02 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAID
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
CN101257800B (en) * 2005-07-18 2012-07-18 好利用医疗公司 Medicaments containing famotidine and ibuprofen
AU2007275360B2 (en) * 2006-07-18 2013-05-16 Horizon Medicines Llc Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
CA2956278C (en) 2008-01-04 2022-03-01 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine and applications thereof
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
BR112014016085A8 (en) 2011-12-28 2017-07-04 Pozen Inc Enhanced compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2015163832A1 (en) * 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
CN116194102A (en) 2020-07-15 2023-05-30 沙巴研究联合有限责任公司 Unit oral dosage composition comprising ibuprofen and famotidine for treating acute pain and reducing the severity and/or risk of heartburn

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
IN171746B (en) * 1989-11-02 1992-12-26 Mcneil Ppc Inc
US4994604A (en) * 1990-01-10 1991-02-19 Merck & Co., Inc. Formation and resolution of ibuprofen lysinate
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9407541A1 *

Also Published As

Publication number Publication date
EP0663839A1 (en) 1995-07-26
MX9306006A (en) 1995-01-31
WO1994007541A1 (en) 1994-04-14
CA2144155A1 (en) 1994-04-14
AU4931693A (en) 1994-04-26
JPH08502254A (en) 1996-03-12

Similar Documents

Publication Publication Date Title
EP0597463A3 (en) Thermotherapiesonde.
DE59403259D1 (en) Tetraaroxyperylen-3,4,9,10-tetracarbonsäurepolyimide
EP0580285A3 (en) Auto-reclosers.
ZA939656B (en) Microvicidal compositions.
EP0598412A3 (en) Skinprotection composition.
HU9202848D0 (en) 1,2-dihydro-2-oxopyridine
EP0671929A4 (en) Compositions.
PH31071A (en) Substituted pyrridopyrimidines useful antgiotensinII antagonists.
EP0633771A4 (en) Compounds.
EP0663839A4 (en) Ibuprofen-h 2? antagonist combinations.
EP0572808A3 (en) Antiblocage-system.
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
EP0668864A4 (en) Substituted biphenylmethylimidazopyridines.
ZA946569B (en) 1,5-Diphenyl-3-pyrazolylalkyl-N-hydroxydithiocarbamates
ZA929590B (en) Diphenylsulphides.
EP0599191A3 (en) Speed-governor-circuit.
DE69205795D1 (en) Mesoprotheseunterlage.
EP0592354A3 (en) Vacuum-centrifuge.
DE69203865D1 (en) Thermo-transferdrucksystem.
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
EP0663819A4 (en) Ibuprofen-caffeine combinations.
ZA929820B (en) Heisswinderschieber.
ZA925725B (en) Qinolin-2-yl-methoxybenzylhydroxyureas.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980421

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980710

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19981028